The Preventive Effects of Neurodynamic Mobilisation
Launched by UĞUR SÖZLÜ · Apr 6, 2022
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
The aim of this study was to investigate the effects of neurodynamic mobilization (NM) technique on muscle damage and inflammation biomarkers, and pain, pressure pain threshold, and functional status in delayed onset muscle soreness (DOMS). In the study, 34 healthy sedentary male volunteers were randomly divided into two groups as NM (n = 17) and SHAM-NM (n = 17). After the initial evaluation of the individuals, femoral nerve NM and placebo NM techniques were administered three sets a day with ten repetitions for three days a week for three weeks. Three days after the end of the application...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Being in the age range of 20-32 years.
- • Being male (Because gender difference in the magnitude of eccentric exercise-induced muscle damage might exist as shown in previous studies, only men were recruited in the present study.)
- • Being inactive according to activity guidelines published by the American College of Sports Medicine (less than 30 minutes of moderate physical activity as five times a week).
- Exclusion Criteria:
- • Absence of DOMS symptoms,
- • History of vascular disease,
- • Recent injury or surgery to their lower extremity,
- • Neurological impairments and regular use of pain and inflammation medications.
About Uğur Sözlü
Uğur Sözlü is a dedicated clinical trial sponsor specializing in the design, management, and execution of innovative clinical research studies. With a commitment to advancing medical science, Uğur Sözlü collaborates with healthcare professionals and research institutions to facilitate the development of new therapies and interventions. The organization emphasizes rigorous ethical standards, patient safety, and data integrity throughout the research process, aiming to contribute valuable insights that enhance treatment options and improve patient outcomes across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Beşevler, Turkey
Patients applied
Trial Officials
Selda Başar, Phd
Study Chair
Gazi University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials